Introduction
Acute myocardial infarction (AMI) is the leading cause of death 1 . Myocardial infarction results from prolonged myocardial ischemia precipitated in most cases by rupture of the pre-existing plaque leading to occlusive thrombus formation in the coronary artery 2 . The introduction of coronary care units decreased Acute MI mortality from 30% to 15%, while the use of thrombolytics further de-creased it to 5-7% 3 . Prompt reperfusion of the occluded artery through Percutaneous coronary angioplasty or thrombolytic therapy decreases the duration of occlusion leading to improved mortality 4 .
Outcome of Patients Having Acute Myocardial Infarction with and without Streptokinase
Observation regarding age, gender, occupation, address, history of smoking, diabetes mellitus, hypertension, family history of ischemic heart disease and time from the symptoms onset to the hospital arrival was noted on a preformed Proforma. Thorough physical examination was carried out in all the patients. Complete blood count, fasting blood sugar, CK-MB level, serum urea, creatinine, lipid profile, chest x-ray and serial ECG's were carried out in all patients. Echocardiography was performed to look for left ventricular ejection fraction and any mechanical complications. All patients were treated as per CCU protocol 14 . Patients were followed till the discharge or death. In-hospital mortality was the primary end point while the developments of complications during the hospital stay were the secondary end points of the study.
All data was analyzed using Statistical Package for Social Sciences version 11.0. Student t test was applied to analyze continuous variables while chi-square test for the categorical ones.
Results
In 340 patients with Acute MI, 218 (64.11%) were in SK group and 122 (35.88%) in the non-SK group. For baseline characteristics in Table-I . No difference of statistical significance was observed between the two groups.
Table-I: Demographic variables of the patients.
In table II-Mean time of arrival to the hospital after symptom onset was 10.41±9.97 hours. Patients in sk group presented earlier than non-sk group, 5.9±4.76 hours' vs 19.39±10.53 hours. In non-sk group 16 (13.1%) had contraindication to thrombolytic therapy Overall in-hospital mortality was 44 (12.9%), with more deaths among patients in non-sk group 25 (20.5%) as compared to 19 (8.7%) in sk group (p=0.002).
Table-II: Characteristics of patients at presentation.
In table-III Complication rate was higher in non-sk group as compared to sk group, p=0.046. LVF was the most common complication 70 (20.6%), it was also the leading cause of death in both the groups; 13 (6%) in sk group and 13 (10.7%) in non-sk group, p<0.0001. VT/VF was the second most common complication 26 (7.6%) and the cause of death in 3 (1.4%) patients in sk and 5 (4.1%) in non-sk group, p<0.0001. Post MI angina occurred in 11 (5%) of cases in sk group as compared to 11 (9%) in non-sk group but was not statistically significant, p>0.05. 
Discussion
Acute myocardial infarction still remains the leading cause of death despite recent advances in its management. SK is the most commonly used thrombolytic agent worldwide. In our study the in-hospital mortality of patients with Acute MI was 8.7% in thrombolysed group and 20.5% in non-thrombolysed group. Our results are consistent with the previous studies 5, [9] [10] [11] 15 . In ISIS-2 the in-hospital mortality was 8% in patients receiving re perfusion as compared to 13% in the non-reperfused group 5 . Data from WIRE registry 9 showed in-hospital mortality of 9.25% in sk group which is also similar to our results. Ahmed et al 
